Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy, Hepatic Insufficiency Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

NCT07401862
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
LY3841136
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

NCT04587622
View directory record Official record
Conditions
Hepatic Failure
Interventions
Icenticaftor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

NCT06190691
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Edgewater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

NCT00859053
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BMS-790052
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Anaheim, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

NCT00416702
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
QAB149
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2008 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

NCT04867941
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

NCT03962049
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
Linzagolix
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

NCT05440344
View directory record Official record
Conditions
Hepatic Insufficiency, Healthy
Interventions
Imlunestrant
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Rialto, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

NCT07110441
View directory record Official record
Conditions
Acute-on-Chronic Liver Failure
Interventions
Single Dose G1090N, Multiple dosing of G1090N
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

NCT05098054
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Jul 22, 2026, 12:27 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease

NCT07677358
View directory record Official record
Conditions
Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults
Interventions
Atirmociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT01860326
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Alisporivir
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

NCT05882032
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
LY3502970
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

NCT03341884
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Ipatasertib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Miami, Florida • Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 22, 2026, 12:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver Donors

NCT01922323
View directory record Official record
Conditions
Liver Insufficiency
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

NCT01019070
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BMS-650032
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Anaheim, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

NCT03968848
View directory record Official record
Conditions
Hepatic Impairment, Hepatic Insufficiency, Healthy Subjects
Interventions
acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

NCT06719128
View directory record Official record
Conditions
Hepatic Insufficiency, Healthy
Interventions
Olomorasib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

NCT02998775
View directory record Official record
Conditions
Hepatic Impairment; Renal Impairment
Interventions
Plasma Sampling
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

NCT03465059
View directory record Official record
Conditions
Hepatic Insufficiency & Healthy Subjects
Interventions
Zanubrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 22, 2026, 12:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

NCT04097704
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Mavorixafor
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Montclair, California • Rialto, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

NCT03842761
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
BI 685509, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 22, 2026, 12:27 PM EDT